Mayer Brown represented leading biotechnology company Adaptimmune Limited on its $104 million Series A financing round led by a group of leading public and private healthcare focused venture funds. UK-based Adaptimmune is focused on the use of T cell therapy with engineered T cell receptors to treat cancer and infectious disease and plans to use the proceeds from the Series A financing to advance the company’s internal programmes into the clinic in multiple cancer indications. The company has clinical operations in Oxford, UK where University of Oxford is a longstanding shareholder and at the University of Pennsylvania.

The Mayer Brown team was led by Corporate & Securities partner David Bakst (New York) and included: Corporate & Securities – partners Todd Bowen (New York) and Richard Smith (London) and senior associate Megan Paul (London); Tax Transactions & Consulting – partners Jason Bazar (New York) and James Hill (London) and senior associate Benjamin Fryer (London) and associate Jared Goldberger (New York); and Employment & Benefits – partner Andrew Stanger (London).